Ontario Teachers Pension Plan Board Has $2.53 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Ontario Teachers Pension Plan Board raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 15.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,616 shares of the company's stock after buying an additional 1,011 shares during the quarter. Ontario Teachers Pension Plan Board's holdings in Medpace were worth $2,530,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. R Squared Ltd bought a new position in Medpace during the fourth quarter worth $30,000. SBI Securities Co. Ltd. bought a new position in shares of Medpace during the 4th quarter worth about $31,000. Jones Financial Companies Lllp raised its position in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after buying an additional 110 shares during the last quarter. Lindbrook Capital LLC lifted its stake in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares during the period. Finally, Assetmark Inc. grew its position in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MEDP has been the subject of several recent research reports. Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target for the company. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Robert W. Baird boosted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Truist Financial dropped their price objective on shares of Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Finally, Mizuho decreased their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Ten equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $357.50.

Medpace Stock Down 0.1 %

MEDP stock traded down $0.22 during trading on Friday, hitting $296.28. The company had a trading volume of 698,291 shares, compared to its average volume of 326,249. The firm has a 50-day moving average price of $318.52 and a 200-day moving average price of $333.29. Medpace Holdings, Inc. has a 12 month low of $272.00 and a 12 month high of $459.77. The stock has a market cap of $8.96 billion, a price-to-earnings ratio of 23.46, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.